Paraneoplastic or not? Sirtuin 2 in anti-N-methyl-d-aspartate receptor encephalitis

Oskar Stevens-Jones1,2, Hana Mojzisova3, Martin Elisak3

  • 1Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden.

PubMed
Abstract

Insights

This study identified 18 protein biomarkers in cerebrospinal fluid differentiating autoimmune encephalitis (AE) from controls. Sirtuin 2 (SIRT2) shows potential as a biomarker for paraneoplastic N-methyl-d-aspartate receptor (NMDAR) encephalitis.

Area of Science:

  • Neuroimmunology
  • Proteomics
  • Biomarker Discovery

Background:

  • Autoimmune encephalitis (AE), including N-methyl-d-aspartate receptor (NMDAR) and leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis, presents significant morbidity.
  • Identifying novel, clinically relevant biomarkers is crucial for diagnosing and managing these conditions.

Purpose of the Study:

  • To investigate novel protein biomarkers in cerebrospinal fluid (CSF) for NMDAR and LGI1 encephalitis using a proteomic approach.
  • To explore potential correlations between identified biomarkers and clinical variables in AE patients.

Main Methods:

  • A retrospective study involving 58 CSF samples from 28 AE patients (14 NMDAR, 14 LGI1) and 30 controls.
  • Proteomic analysis using Olink Target 96 Inflammation panel to measure 92 proteins in each CSF sample.
  • Statistical analysis correlating protein levels with clinical data.

Main Results:

  • Eighteen protein biomarkers significantly differed between AE patients and controls.
  • In NMDAR encephalitis, Sirtuin 2 (SIRT2), TNFβ, and CD5 were associated with ovarian teratoma.
  • SIRT2 levels correlated positively with age and total hospital days in NMDAR encephalitis patients.

Conclusions:

  • Sirtuin 2 (SIRT2) demonstrates potential as a biomarker for identifying the paraneoplastic etiology in N-methyl-d-aspartate receptor (NMDAR) encephalitis.
  • Further investigation of SIRT2 is warranted for its clinical utility in NMDAR encephalitis.